Citi is so bullish on one biotech firm that it has given its shares a target price that represents around 800% upside.
In a Nov. 22 note, Citi gave the stock a buy rating and a price target of $90, representing potential upside of around 818% from Tuesday's price.
However, the bank cautioned that the stock is high risk, given the "typical volatility" of biotech stocks and uncertainty associated with clinical trials.
According to FactSet, analysts covering the stock give it average price target upside of 385% and a buy rating of 88%.
On FactSet, the highest estimate came from Oppenheimer, which gives it potential upside of over 600%.
Persons:
—, Oppenheimer, — CNBC's Michael Bloom
Organizations:
Citi, Citi isn't, BMO Capital Markets, BMO, P Biotech ETF, Biotech
Locations:
U.S